This is a working overview of GHRH receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-12-18. Anything still debated is marked as such rather than presented as settled.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH analog, not a steroid |
| Backbone length | 29 amino acids | Based on GRF(1-29) |
| Substitutions | Four positions | D-Ala2, Gln8, Ala15, Leu27 |
| Appearance | White to off-white powder | Typical lyophilized research material |
| Common synonyms | Modified GRF(1-29) | Usage varies between sources |
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
frequent blood glucose monitoring (8–10 times daily); continuous blood glucose monitoring; logging and review of blood glucose values, searching for patterns of low blood sugar values; conservative increases in insulin delivery; awareness to the signs of hypoglycemia; awareness to hyperglycemia in response to increased delivery of insulin; use of appropriate types of insulin (long-acting, short-acting, etc.) in appropriate amounts.
The Soviets planned to use the GIUK gap to intercept any NATO ships, especially aircraft carriers, heading towards the Soviet Union. Ships and submarines as well as Tupolev Tu-142 maritime-surveillance aircraft aimed to track any threatening ships. The advent of longer-ranged Soviet submarine-launched ballistic missiles (SLBMs) allowed the Soviet Navy to deploy their ballistic missile submarine (SSBNs) within protected bastions in the Barents Sea and reduced their need to transit the GIUK gap. The much reduced, post-Cold War Russian Navy has even less need to transit the GIUK gap. Crossing the GIUK gap was a major strategic move for Ocean Venture in 1992, in which 84 NATO ships, including 4 US aircraft carriers, departed from their usual August exercise pattern, deployed a decoy south toward the mid-Atlantic, and then entered waters in a move that had historically been associated with a risk of destabilizing détente.
== See also == Ki Database Ion channel linked receptors Neuropsychopharmacology Schild regression for ligand receptor inhibition Signal transduction Stem cell marker List of MeSH codes (D12.776) Receptor theory
The gamma-emitting isotopes iodine-123 (half-life 13.223 hours), and (less commonly) the longer-lived and less energetic iodine-125 (half-life 59.392 days) are used as nuclear imaging tracers to evaluate the anatomic and physiologic function of the thyroid. Abnormal results may be caused by disorders such as Graves' disease or Hashimoto's thyroiditis. Both isotopes decay by electron capture (EC) to the corresponding tellurium nuclides, but in neither case are these the metastable nuclides 123mTe and 125mTe (which are of higher energy, and are not produced from radioiodine). Instead, the excited tellurium nuclides decay immediately (half-life too short to detect). Following EC, the excited 123Te from 123I emits a high-speed 127 keV internal conversion electron (not a beta ray) about 13% of the time, but this does little cellular damage due to the nuclide's short half-life and the relatively small fraction of such events. In the remainder of cases, a 159 keV gamma ray is emitted, which is well-suited for gamma imaging. Excited 125Te resulting from electron capture of 125I also emits a much lower-energy internal conversion electron (35.5 keV), which does relatively little damage due to its low energy, even though its emission is more common. The relatively low-energy gamma from 125I/125Te decay is poorly suited for imaging, but can still be seen, and this longer-lived isotope is necessary in tests that require several days of imaging, for example, fibrinogen scan imaging to detect blood clots.
==== Exocytosis ==== Exocytosis is the process by which a cell transports molecules such as neurotransmitters and proteins out of the cell. As an active transport mechanism, exocytosis requires the use of energy to transport material. Exocytosis and its counterpart, endocytosis, the process that brings substances into the cell, are used by all cells because most chemical substances important to them are large polar molecules that cannot pass through the hydrophobic portion of the cell membrane by passive transport. Exocytosis is the process by which a large amount of molecules are released; thus it is a form of bulk transport. Exocytosis occurs via secretory portals at the cell plasma membrane called porosomes. Porosomes are permanent cup-shaped lipoprotein structures at the cell plasma membrane, where secretory vesicles transiently dock and fuse to release intra-vesicular contents from the cell. In the context of neurotransmission, neurotransmitters are typically released from synaptic vesicles into the synaptic cleft via exocytosis; however, neurotransmitters can also be released via reverse transport through membrane transport proteins.
Sources: en.wikipedia.org
Prior data before the current census, Bromley Town, 18.5% of the population was of minority ethnicity. The highest in the town was 19.3% in Plaistow and Sundridge, and the lowest was 8.3% in Hayes and Coney Hall.
When the term became common in jewelry making, "marcasite" referred to all iron sulfides including pyrite, and not to the eponymous orthorhombic FeS2 mineral marcasite, which is lighter in color, brittle and chemically unstable, and thus not suitable for jewelry making. Pyrite gained a brief popularity in the 16th and 17th centuries as a source of ignition in early firearms, most notably the wheellock, where a sample of pyrite was placed against a circular file to strike the sparks needed to fire the gun. During the early years of the 20th century, pyrite was used as a mineral detector in radio receivers, and is still used by crystal radio hobbyists. Until the vacuum tube matured, the crystal detector was the most sensitive and dependable detector available—with considerable variation between mineral types and even individual samples within a particular type of mineral. Pyrite detectors occupied a midway point between galena detectors and the more mechanically complicated perikon mineral pairs. Pyrite detectors can be as sensitive as a modern 1N34A germanium diode detector.
== Function in protein termination == Protein elongation continues until a stop codon appears on the mRNA. A Class I release factor (RF1 or RF2) binds to the stop codon, which induces hydrolysis of the tRNA-peptide bond in the P site, allowing the newly-formed protein to exit the ribosome. The nascent peptide continues to fold and leaves the 70S ribosome, the mRNA, the deacylated tRNA (P site), and the Class I release factor (A site). In a GTP-dependent manner, the subsequent recycling is catalyzed by a Class II release factor named RF3/prfC, Ribosome recycling factor (RRF), Initiation Factor 3 (IF3) and EF-G. The protein RF3 releases the Class I release factor so that it may occupy the ribosomal A site. EF-G hydrolyzes GTP and undergoes a large conformational change to push RF3 down the ribosome, which occurs alongside tRNA dissociation and promotes the ribosomal subunit rotation. This motion actively splits the B2a/B2b bridge, which connects the 30S and the 50S subunits, so that the ribosome can split. IF3 then isolates the 30S subunit to prevent re-association of the large and small subunits.
In mountainous areas, they seek southerly slopes at lower elevations for forage and move to northerly and easterly slopes at higher elevations as summer progresses. The time that American black bears emerge from hibernation varies. Factors affecting this include temperature, flooding, and hunger. In southern areas, they may wake up in midwinter. Further north, they may not be seen until late March, April, or even early May. Altitude also has an effect. Bears at lower altitudes tend to emerge earlier. Mature males tend to come out earliest, followed by immature males and females, and lastly mothers with cubs. Mothers with yearling cubs are seen before those with newborns.
=== Chronology of boxed warnings === In 2008, the U.S. FDA added black box warnings on all fluoroquinolones, advising of the increased risk of tendon damage. In 2016, the FDA found that systemic use (by mouth or injection) of fluoroquinolones was associated with "disabling and potentially permanent serious side effects" involving the tendons, muscles, joints, nerves, and central nervous system, concluding that these side effects generally outweigh the benefits for people with acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections when other treatment options are available. Concerns regarding low blood sugar and mental health problems were added in 2018. In December 2018, the FDA issued a warning regarding an increased risk of aortic aneurysms and aortic dissections associated with fluoroquinolone use. This warning specifically targeted older adults and patients with conditions such as hypertension, Marfan syndrome, Ehlers–Danlos syndrome, atherosclerosis, peripheral vascular disease, and a history of aneurysms.
Sources: en.wikipedia.org
=== Ultrasound imaging === Imaging the urogenital system via an ultrasound is the first-line imaging test for hypospermia. This assessment looks out for testicular degeneration, testicular anomalies, and carry out a detailed study of the deep genital tract and glands using a high endorectal probe frequency. This examination makes it possible to visualize the vas deferens over their pelvic path and therefore to diagnose possible agenesis (absence of cells within organs) on portions not accessible to clinical examination.
== Playing career == Because the population of Duttlenheim was short in numbers, it proved difficult to field a team of 11 players of equal ages; Wenger did not play for FC Duttlenheim until the age of 12. Claude Wenger, a teammate of Arsène's, noted his lack of pace as a player, which he made up for with his "ability to guard the ball, [seeming] to have a complete vision of the pitch and having an influence among his team-mates", according to Marcel Brandner, the president of FC Duttlenheim. As a young teenager, he was called Petit; the nickname ceased when he had a growth spurt and broke into FC Duttlenheim's first team, aged 16. The team did not have a coach to prepare the players tactically, rather a person who supervised training sessions. Wenger took it upon himself to manage the side, with Claude stating "Arsène wasn't the captain and yet he was. It was 'You do this, you do that, you do this, you do that.' He was the leader".
The new 16th district is entirely within El Paso County, taking in El Paso and such surrounding suburbs as Socorro, Horizon City, and Anthony. The incumbent is Democrat Veronica Escobar, who was re-elected with 59.5% of the vote in 2024. In 2024, Kamala Harris won 57.4% of the vote in this heavily Hispanic district, where Colin Allred also won with 58.4% of the vote.
Esophageal varices are swollen twisted branches of the azygous vein in the lower third of the esophagus. These blood vessels anastomose (join up) with those of the portal vein when portal hypertension develops. These blood vessels are engorged more than normal, and in the worst cases may partially obstruct the esophagus. These blood vessels develop as part of a collateral circulation that occurs to drain blood from the abdomen as a result of portal hypertension, usually as a result of liver diseases such as cirrhosis. This collateral circulation occurs because the lower part of the esophagus drains into the left gastric vein, which is a branch of the portal vein. Because of the extensive venous plexus that exists between this vein and other veins, if portal hypertension occurs, the direction of blood drainage in this vein may reverse, with blood draining from the portal venous system, through the plexus. Veins in the plexus may engorge and lead to varices. Esophageal varices often do not have symptoms until they rupture. A ruptured varix is considered a medical emergency because varices can bleed a lot. A bleeding varix may cause a person to vomit blood, or suffer shock. To deal with a ruptured varix, a band may be placed around the bleeding blood vessel, or a small amount of a clotting agent may be injected near the bleed. A surgeon may also try to use a small inflatable balloon to apply pressure to stop the wound. IV fluids and blood products may be given in order to prevent hypovolemia from excess blood loss.
Sources: en.wikipedia.org
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.
The original material included a linker that binds serum albumin. A later variant removed that linker to reduce the duration of action. Catalogs and papers did not consistently adopt separate names, so both remain widely labeled with the same term.
The amino acid sequence and the presence or absence of the linker group. Mass measured by spectrometry gives an independent check that separates the two forms.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.